Atossa Therapeutics, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Atossa Therapeutics, Inc. has filed its 2023 annual report on Form 10-K, providing a comprehensive overview of its financial health and business operations.</b>

AI Summary

ATOSSA THERAPEUTICS, INC. (ATOS) filed a Annual Report (10-K) with the SEC on April 1, 2024. Atossa Therapeutics, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The filing details financial information, business operations, and risk factors for the company. Key financial instruments mentioned include Series A and Series B Convertible Preferred Stock, and various warrants. The company's business address is 107 Spring Street, Seattle, WA 98104. The report covers the fiscal year ending December 31, 2023, with a filing date of April 1, 2024.

Why It Matters

For investors and stakeholders tracking ATOSSA THERAPEUTICS, INC., this filing contains several important signals. This 10-K filing provides investors with crucial, up-to-date information on Atossa's financial performance, strategic initiatives, and potential risks, enabling informed investment decisions. The detailed disclosure of financial instruments, including preferred stock and warrants, offers insight into the company's capital structure and potential future dilution.

Risk Assessment

Risk Level: medium — ATOSSA THERAPEUTICS, INC. shows moderate risk based on this filing. The company's financial disclosures in this 10-K are extensive, covering various financial instruments and expenses, but specific revenue and profitability figures for the current period are not detailed in the provided header information, suggesting a need for deeper analysis of the full report.

Analyst Insight

Investors should review the full 10-K filing to understand the company's financial performance, R&D pipeline, and any significant changes in its capital structure.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reported period)
• 2024-04-01 — Filing Date (Date of submission)
• 2834 — SIC Code (Pharmaceutical Preparations)
• DE — State of Incorporation (Company's incorporation state)
• 2010-03-25 — Date of Name Change (Former company name was Atossa Genetics Inc.)

Key Players & Entities

• ATOSSA THERAPEUTICS, INC. (company) — Filer name
• ATOS (company) — Ticker symbol
• 10-K (filing) — Form type
• 2024-04-01 (date) — Filing date
• 2023-12-31 (date) — Fiscal year end
• 107 SPRING STREET (address) — Business address
• SEATTLE (location) — Business address city
• WA (location) — Business address state

FAQ

Risk Factors

• Financial Instruments [medium — financial]: The filing mentions various financial instruments including Series A and Series B Convertible Preferred Stock, and different series of warrants, indicating potential complexities in the company's capital structure.
• Business Operations [medium — operational]: The report details the company's business, which is in the pharmaceutical preparations sector (SIC 2834), but specific operational updates or challenges are not detailed in the header.

Key Dates

• 2023-12-31: Fiscal Year End — The end date for the reporting period covered by the 10-K.
• 2024-04-01: Filing Date — The date the 10-K was officially submitted to the SEC.
• 2010-03-25: Name Change — Date when the company changed its name from Atossa Genetics Inc.

Key Financial Figures

• $0.18 — nge on which registered Common Stock, $0.18 par value ATOS The Nasdaq Capital M
• $0 — he registrant's common stock, par value $0.18, as of March 15, 2024, was 125,304,0
• $500,000 — elivered systemically can be as high as $500,000 per patient. We have filed patent app
• $1 billion — atment and prevention settings is up to $1 billion annually. The American Cancer Society (
• $88.5 million — h and cash equivalents of approximately $88.5 million. Potential Uses of Capital Resources
• $17.3 million — er 31, 2023 and 2022 were approximately $17.3 million and $15.1 million, respectively. Inte
• $15.1 m — 22 were approximately $17.3 million and $15.1 million, respectively. Intellectual Pro

Filing Documents

• atos-20231231.htm (10-K) — 2116KB
• atos-ex10_12.htm (EX-10.12) — 107KB
• atos-ex10_13.htm (EX-10.13) — 16KB
• atos-ex21_1.htm (EX-21.1) — 1KB
• atos-ex23_1.htm (EX-23.1) — 6KB
• atos-ex23_2.htm (EX-23.2) — 6KB
• atos-ex31_1.htm (EX-31.1) — 13KB
• atos-ex31_2.htm (EX-31.2) — 13KB
• atos-ex32_1.htm (EX-32.1) — 8KB
• atos-ex32_2.htm (EX-32.2) — 9KB
• atos-ex97_1.htm (EX-97.1) — 32KB
• img83880236_0.jpg (GRAPHIC) — 345KB
• img95494516_0.jpg (GRAPHIC) — 125KB
• 0000950170-24-039306.txt (&nbsp;) — 7785KB
• atos-20231231.xsd (EX-101.SCH) — 999KB
• atos-20231231_htm.xml (XML) — 846KB

Business

Business 5 Item 1A.

Risk Factors

Risk Factors 18 Item 1B. Unresolved Staff Comments 37 Item 1 C. Cybersecurity 37 Item 2.

Properties

Properties 38 Item 3.

Legal Proceedings

Legal Proceedings 38 Item 4. Mine Safety Disclosures 38 PART II Item 5. Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 39 Item 6. Reserved 39 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 40 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 46 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 46 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 46 Item 9A.

Controls and Procedures

Controls and Procedures 46 Item 9B. Other Information 47 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 47 PART III Item 10. Directors, Executive Officers and Corporate Governance 48 Item 11.

Executive Compensation

Executive Compensation 50 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 56 Item 13. Certain Relationships and Related Transactions, and Director Independence 57 Item 14. Principal Accountant Fees and Services 58 PART IV Item 15. Exhibits and Financial Statement Schedules 60 Item 16 . Form 10-K Summary 60

Signatures

Signatures 79 2 Table of Contents NOTE REGARDING FORWARD-LOOKING STATEMENTS All statements made in this Annual Report on Form 10-K (this Annual Report) that are not statements of historical fact, including statements regarding guidance, industry prospects or future results of operations or financial position, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act) and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). We have made these statements in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are subject to certain risks and uncertainties, which could cause actual results, outcomes and the timing of results or outcomes to differ materially from those projected or anticipated. Although we believe that our assumptions underlying our forward-looking statements are reasonable as of the date of this Annual Report we cannot assure you that the forward-looking statements set out in this Annual Report will prove to be accurate. We may identify these forward-looking statements by the use of forward-looking words, including, but not limited to, such as "expect," "potential," "continue," "may," "will," "should," "could," "would," "seek," "intend," "plan," "estimate," "anticipate," "future," "believe," "design," "predict," "potential" or the negative versions of these words or other similar expressions. Forward-looking statements contained in this Annual Report include, but are not limited to, statements about: general macroeconomic conditions, including the impact of inflation, high interest rates, general economic slowdown or a recession, the prospect of a shutdown of the U.S. federal government, foreign exchange rate volatility, financial institution instability, changes in monetary policy and increasing geopolitical instability, including the conflict in Ukraine, the conflict in the Middle E

View Full Filing

View this 10-K filing on SEC EDGAR